Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research note issued to investors on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Stock Performance

NASDAQ GLMD opened at $2.63 on Friday. The stock has a market cap of $1.68 million, a price-to-earnings ratio of -0.16 and a beta of 0.66. The business has a 50 day simple moving average of $2.94 and a 200 day simple moving average of $3.71. Galmed Pharmaceuticals has a 52-week low of $2.56 and a 52-week high of $23.80.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.